Request Demo
Last update 09 May 2026
Semaglutide Biosimilar(Shandong New Time)
Last update 09 May 2026
Overview
Basic Info
Drug Type Recombinant polypeptide, Biosimilar |
Synonyms Semaglutide Biosimilar (Shandong New Time Pharmaceutical Co. Ltd.), 司美格鲁肽 生物类似药（Shandong New Time Pharmaceutical Co. Ltd.） |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 50953
The sequence is quoted from: *****
Related
4
Clinical Trials associated with Semaglutide Biosimilar(Shandong New Time)CTR20252373
司美格鲁肽注射液与诺和泰®在2型糖尿病患者中的有效性和安全性的多中心、随机、开放、平行对照、Ⅲ期临床研究
[Translation] A multicenter, randomized, open, parallel-controlled, phase III clinical study on the efficacy and safety of semaglutide injection and Novotel® in patients with type 2 diabetes
CTR20250556
司美格鲁肽注射液与诺和盈®在肥胖患者中的有效性和安全性的多中心、随机、开放、平行对照、Ⅲ期临床研究
[Translation] A multicenter, randomized, open, parallel-controlled, phase III clinical study on the efficacy and safety of semaglutide injection and Novartis® in obese patients
CTR20251083
评价司美格鲁肽注射液与诺和泰®在健康成人研究参与者中的药代动力学及安全性的随机、开放、单次给药、两制剂、平行设计的Ⅰ期临床研究
[Translation] A randomized, open-label, single-dose, two-drug, parallel-design phase I clinical study to evaluate the pharmacokinetics and safety of semaglutide injection and Novotel® in healthy adult study participants
100 Clinical Results associated with Semaglutide Biosimilar(Shandong New Time)
Login to view more data
100 Translational Medicine associated with Semaglutide Biosimilar(Shandong New Time)
Login to view more data
100 Patents (Medical) associated with Semaglutide Biosimilar(Shandong New Time)
Login to view more data
100 Deals associated with Semaglutide Biosimilar(Shandong New Time)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | Phase 3 | China | 25 Sep 2025 | |
| Obesity | Phase 3 | China | 29 Aug 2025 | |
| Cardiovascular Diseases | Phase 1 | China | 13 Nov 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free